Evidence map›Paper›PMID 40794246›Full record

ArticleJournal of neuro-oncology2025

Impact of healthcare disparities on the treatment and survival of patients with high-grade gliomas in Colombia: a multicenter inverse probability-weighted cohort analysis.

Esteban Ramirez Ferrer, Juan Pablo Zuluaga-Garcia, Juan Diego Alzate, Juliana Mayorga-Corvacho, Maria Alejandra Sierra, Maria Osley Garzon-Duque, Alberto Daza-Ovalle, Humberto Madrinan-Navia, Mauricio Riveros-Castillo

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Esteban Ramirez FerrerDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. eramirez14@mdanderson.org.ORCID http://orcid.org/0000-0002-2775-0157
Juan Pablo Zuluaga-GarciaDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-6862-3752
Juan Diego AlzateDepartment of Neurosurgery, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0001-5663-8722
Juliana Mayorga-CorvachoDepartment of Neurosurgery, Hospital Universitario La Samaritana, Bogota, Colombia.ORCID http://orcid.org/0000-0001-7753-7533
Maria Alejandra SierraDepartment of Neurosurgery, Center of Research and Training in Neurosurgery, Bogota, Colombia.ORCID http://orcid.org/0009-0002-5675-2669
Maria Osley Garzon-DuqueSchool of Medicine, Universidad CES, Medellin, Colombia.ORCID http://orcid.org/0000-0001-7261-3146
Alberto Daza-OvalleDepartment of Neurosurgery, Hospital Universitario La Samaritana, Bogota, Colombia.
Humberto Madrinan-NaviaDepartment of Neurosurgery, Fundación Valle del Lili, Cali, Colombia.ORCID http://orcid.org/0000-0001-7862-4057
Mauricio Riveros-CastilloDepartment of Neurosurgery, Hospital Universitario La Samaritana, Bogota, Colombia.ORCID http://orcid.org/0000-0003-3978-2153

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeExplore the impact of healthcare disparities in patients with high-grade glioma (HGG) in the Colombia's universal healthcare model setting, aiming to assess access to adjuvant treatment and survival outcomes among HGG patients covered under contributory versus subsidized insurance schemes in Bogotá, Colombia.

methodsA retrospective cohort study was conducted in two academic neurosurgical centers in Bogotá, Colombia, each serving patient populations with a differential distribution by insurance scheme. Adult patients with newly diagnosed high-grade glioma (HGG) who underwent surgical management between 2017 and 2021 were included. Patients with recurrent disease at presentation or lost to follow-up after surgery were excluded. Demographic, clinical, surgical, and treatment data were collected. The primary outcome was overall survival, assessed through medical records and the national death registry. A propensity score model with inverse probability of treatment weighting (IPTW) was used to adjust for confounding. Cox proportional hazards and logistic regression models were applied.

resultsA total of 113 patients were included; 88 had contributory coverage and 25 had subsidized coverage. Patients in the subsidized group had significantly lower rates of postoperative medical oncology consultation (48% vs. 84%, 95% p < 0.001), chemotherapy (28% vs. 68.2%, p < 0.001), and radiotherapy (8% vs. 56.3%, p < 0.001). Median overall survival was significantly lower in the subsidized group (9.8 vs. 16.5 months, p = 0.006). After IPTW adjustment, subsidized insurance (HR 1.66, 95% CI 1.03-2.68, p = 0.035), subtotal resection (HR 1.58, 95% CI 1.01-2.49, p = 0.045), and lack of oncology consultation (HR 5.24, 95% CI 1.21-22.63, p = 0.026) were independently predicted worse survival. Female sex (OR 2.59, p = 0.045) and subsidized coverage (OR 8.21, p < 0.001) were associated with failure to complete oncology follow-up.

conclusionsIn the context of a universal healthcare system such as Colombia's, differences in access to adjuvant therapy may contribute to survival disparities among patients with high-grade gliomas. While formal insurance coverage is broadly available, it does not necessarily ensure timely or equitable care delivery. Additionally, our findings suggest that gender-related factors may influence access to postoperative oncology care. Efforts to strengthen care coordination, address structural barriers, and ensure equitable access across insurance types and sexes could help improve outcomes in this population.

Indexed as

Brain NeoplasmsGliomaHealthcare DisparitiesAdultAgedColombiaFemaleFollow-Up StudiesHealth Services AccessibilityHumansMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateYoung AdultAdjuvant therapyHealthcare disparitiesHigh-grade gliomaInsurance providersOutcomes

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.